HOME >> MEDICINE >> NEWS
Neural transplants provide persistent benefit in patients with Huntington's disease

Neuronal transplantation in Huntington's disease provides a period of improvement and stability of several years, according to an Article published online today (Monday February 27, 2006) by The Lancet Neurology.

Intracerebral cell therapy, which aims to substitute striatal neurons lost to Huntington's disease by striatal neuroblasts and neural precursors obtained from embryos after elective abortion, has proven beneficial in patients with the disease. Theoretical projection models suggest that the clinical effects of grafting will lead to an initial improvement followed by a period of secondary decline due to the ongoing disease process. However, follow-up has not been long enough to assess the duration of clinical benefit of the treatment up to now.

Anne-Catherine Bachoud-Lvi (Henri Mondor Hospital, France) and colleagues have previously shown, in a pilot study, that intracerebral neural grafts lead to motor and cognitive improvement in patients with Huntington's disease 2 years after the procedure. In their current article, they present data for five patients from their pilot study, assessed annually for up to 6 years after neural grafting.

The procedure provided long-term clinical benefits to three patients in parallel with long-lasting focal improvement in brain metabolic activity. Progression of the disease led to heterogeneous secondary clinical alterations and changes of cerebral metabolism.

Whereas neuronal transplantation is not a permanent cure for Huntington's disease, it does provide a period of improvement and stability. Although neuroprotective treatment seems to be unavoidable in the disease, improvement of the surgical procedure and in patient selection could improve the therapeutic value of neuronal transplantation. Bachoud-Lvi concludes: "Neuroprotection could stop the disease, but only a graft can restore lost function."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
26-Feb-2006


Page: 1

Related medicine news :

1. Neural networking nanotubes
2. Neural development protein disproved as marker for schizophrenia
3. Neural cell transplants fight immune attack in mice with multiple sclerosis
4. Thymus transplants gives hope to babies with fatal immune disease
5. Outcomes for patients with hepatitis B who need liver transplants
6. Women given liver transplants outlive male recipients by around 4 years
7. How tumors respond to treatment prior to liver transplants may be useful in selecting recipients
8. National trial gives unprecedented support for steroid withdrawal in kidney transplants
9. Organ transplants just as successful in those with mental retardation
10. Liver transplants can be successful in HIV patients with Hepatitis B
11. Stem cell transplants improve recovery in animal models for stroke, cerebral palsy

Post Your Comments:
(Date:10/27/2014)... CA and San Diego, CA (PRWEB) October 27, ... nurse quality indicators database, kicks off its Reliability ... at the U.S. Grant Hotel in downtown San ... experts in a dynamic exchange to advance hospital’s ... , “This year’s conference keynote speakers exemplify the ...
(Date:10/27/2014)... Jiwa Law Corporation now provides Vancouver personal ... motor vehicle accidents. The corporation now assists clients in ... up to a maximum of $150,000. These accident benefits ... medications, home support services, and medical equipment. , ... the way you live your life,” states a company ...
(Date:10/27/2014)... and Atlanta, GA (PRWEB) October 27, 2014 ... cloud-based technologies for the healthcare market, and financial ... offer a fully integrated payment and security solution ... EHR is a cloud-based online, ambulatory Electronic Health ... for small and medium-sized practices. Through the ChARM ...
(Date:10/27/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... hospitals have infection control procedures in place to effectively and ... the 1,039 acute care hospitals that responded to the survey, ... percent said they were "not prepared," according to the Association ... results of the poll paint a disturbing picture, and point ...
(Date:10/27/2014)... Medicines Agency (EMA), an EU agency, has gathered information ... the European ADR database, EudraVigilance. Both authorities and pharmaceutical ... to the database, which provides new knowledge about unknown ... adverse drug reaction reports on asthma medications approved for ... period (2007 to 2011). In the light of the ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders to Address Reliability and Resiliency in Hospitals 2Health News:Jiwa Law Corporation Now Assists Clients With ICBC Claims for Motor Vehicle Accidents 2Health News:MedicalMine and Bluefin Payment Systems Partner for Integrated Patient Payments in the ChARM EHR Software Platform 2Health News:MedicalMine and Bluefin Payment Systems Partner for Integrated Patient Payments in the ChARM EHR Software Platform 3Health News:Few U.S. Hospitals Ready to Handle Ebola, Survey Finds 2Health News:Few U.S. Hospitals Ready to Handle Ebola, Survey Finds 3Health News:Adverse drug reactions in children following use of asthma medications 2
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
Cached News: